The mRNA Synthesis and Manufacturing Services Market Size is valued at USD 49,152.2 Million in 2022 and is predicted to reach USD 51,603.6 Million by the year 2031 at a 0.8% CAGR during the forecast period for 2023-2031.
In 2021 market has grown exponentially due to the success of the COVID-19 vaccines, and it has created a massive demand for a consistent supply of vaccines. However, in 2022 market is expected to decrease at the growth rate of -42.0%. The mRNA Synthesis and Manufacturing Services market other than COVID 19 application are under development which offers immense growth and penetration opportunities in the forecast period. By region, Asia Pacific dominates the mRNA synthesis and manufacturing services market with share of 33.4% of total global market.
Due to its versatile and flexible nature, mRNA is an excellent platform for developing prophylactic or therapeutic vaccines against various chronic and infectious diseases. Compared to conventional medicines, mRNA vaccines have higher effectiveness, improved immunogenicity, and required less manufacturing cost. The constant innovations and improvements in mRNA synthesis and manufacturing services are expected to propel the market growth of mRNA synthesis and manufacturing services over the forecast period. During the current Covid-2019 pandemic, many companies have chosen mRNA vaccine technology to combat coronavirus.
For instance, in November 2020, Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.
The increasing need for gene therapies, growing chronic and infectious diseases, and the rising number of clinical trials for cancer therapies and infectious diseases are likely to evolve the mRNA synthesis and manufacturing services market at a considerable rate in the next few years. Furthermore, advanced medical technologies, increasing customizable facilities, improving quality and efficacy services, and novel innovations by pharmaceutical companies enhance the market growth.
However, the lack of flexible, sustainable, and cost-effective manufacturing processes hinders the growth of mRNA synthesis and manufacturing services.Segmentation of mRNA synthesis and manufacturing services market includes Products, Applications, Scale of Operation, and Region. The market can be segmented into API and Drug Products based on Products. By Applications, the market is categorized into Infectious Disease Vaccines, Other Vaccines, Therapeutics and Others. Based on the Scale of Operation, the market is segmented into Research / Preclinical, Clinical, and Commercial. Regionally, the mRNA synthesis and manufacturing services market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe and the Asia Pacific, holds the maximum share of this market due to increased research and development expenditure, increased prevalence of infectious diseases, and the fast adoption of advanced technologies.
Recent Developments:
- In Sept 2022, Lonza and Touchlight have teamed up to deliver end-to-end solutions for mRNA.Through this collaboration, Lonza can expand its end-to-end offering for mRNA manufacture by providing an additional and differentiated supply of DNA raw material in the form of Touchlight's doggybone DNA (dbDNATM). Touchlight's synthetic DNA is produced using an enzymatic method that does not include the use of cells, resulting in increased speed, quality, capacity, and scalability.
- In Aug 2022, The United States granted Arcturus a financial award of $63.2 million, the company disclosed. To accelerate response efforts to the pandemic, the government will fund the development of a self-amplifying mRNA vaccine. Arcturus intends to augment its current influenza vaccine program with the assistance of the Biomedical Advanced Research and Development Authority. This expansion will encompass the creation of a pandemic influenza vaccine, which will be constructed upon the organization's exclusive self-amplifying mRNA platform. This undertaking will be executed utilizing the organization's current influenza vaccine program.
Competitive Landscape
Some major key players in the mRNA Manufacturing and Synthesis Services Market:
CDMO Organizations
- eTheRNA (Etherna Immunotherapies),
- Celonic AG
- Corden Pharma GmbH
- Lonza Group AG
- Rentschler Biopharma
- Laboratorios Farmacéuticos Rovi, S.A.
- Samsung Biologics
- Thermo Fisher Scientific
- Sartorius AG (BIA Separations)
- AGC Biologics
- FUJIFILM Diosynth Biotechnologies
- Hanmi Pharmaceutical
- Arranta Bio
- ST Pharm
- BioCina Pty Ltd.
- Curia Global, Inc.
Custom Synthesis/cGMP Service Providers:
- Eurogentec
- Aldevron
- bioSYNTHESIS
- TriLink BioTechnologies
- Biomay
- Jena Biosciences
- APExBIO
- CELLSCRIPT
- New England Biolabs
- Kernal Biologics
mRNA Manufacturing and Synthesis Services Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 49,152.2 Million |
|
Revenue Forecast In 2031 |
USD 51,603.6 Million |
|
Growth Rate CAGR |
CAGR of 0.8 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Industry, Application, Scale of operations, Product |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia; |
|
Competitive Landscape |
eTheRNA (Etherna Immunotherapies), Celonic AG, Corden Pharma GmbH, Lonza Group AG, Rentschler Biopharma, Laboratorios Farmacéuticos Rovi, S.A., Samsung Biologics, Thermo Fisher Scientific, Sartorius AG (BIA Separations), AGC Biologics, FUJIFILM Diosynth Biotechnologies, Hanmi Pharmaceutical, Arranta Bio, ST Pharm, BioCina Pty Ltd., Curia Global, Inc. and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
